Daiichi Sankyo Co Ltd - Company Profile
Powered by
All the data and insights you need on Daiichi Sankyo Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Daiichi Sankyo Co Ltd Strategy Report
- Understand Daiichi Sankyo Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Daiichi Sankyo Co Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Oncology: | Olmetec |
Trastuzumab Deruxtecan | Benicar |
Pexidartinib | Benicar HCT |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In April, the company and AstraZeneca secured approval from the US Food and Drug Administration for datopotamab deruxtecan (Dato-DXd), a new treatment for a subset of breast cancer patients. |
2024 | Regulatory Approval | In April, the company and AstraZeneca secured approval from the US Food and Drug Administration for ENHERTU for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors. |
2024 | Plans/Strategy | In March, the company and Mitsubishi Tanabe Pharma announced plans to end their marketing alliance agreement for certain drugs, Tenelia Tablets and Tenelia OD Tablets. |
Competitor Comparison
Key Parameters | Daiichi Sankyo Co Ltd | Merck & Co Inc | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | United States of America | Japan | Japan | Japan |
City | Chuo-Ku | Kenilworth | Chuo-Ku | Chuo-Ku | Chuo-Ku |
State/Province | Tokyo | New Jersey | Tokyo | Tokyo | Tokyo |
No. of Employees | 17,435 | 72,000 | 49,095 | 14,484 | 7,604 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Sunao Manabe | Chairman; Chief Executive Officer | Executive Board | 2023 | - |
Hiroyuki Okuzawa | President; Director; Chief Operating Officer | Executive Board | 2023 | - |
Takashi Fukuoka | Chief Strategy Officer; Senior Executive Officer; Director; Head- Global Corporate Strategy | Executive Board | 2023 | - |
Shoji Hirashima | Director; Head - Japan Business Unit; Senior Executive Officer | Executive Board | 2022 | - |
Masahiko Ohtsuki | Chief Digital Transformation Officer; Director; Head- Global DX; Senior Executive Officer | Executive Board | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer